Antengene was successfully listed on The Stock Exchange of Hong Kong Limited

Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor) in Mainland China for the Treatment of Myelodysplastic Syndrome

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

IND approval for the TOUCH trial with respect to ATG-010 (selinexor) was received in mainland China

Our licensed rights under the license agreement with Karyopharm were expanded to 17 APAC countries and regions

Our Group completed the Series C financing with an aggregate amount of approximately US$97 million

IND approval for the BUNCH trial with respect to ATG-008 (onatasertib) was received in mainland China

IND approval for the ERASER trial with respect to ATG-017 was received in Australia

Our Drug Discovery Center commenced operation in Shanghai

Our Manufacturing Center commenced operation in Zhejiang Province